Levodopa
Research News and Information

Sunday, November 22, 2009

[Dopamine agonist therapy in early Parkinson's disease. A survey of a Cochrane review]

3 Oct 2009 The Cochrane analysis confirms some well-known facts: initial therapy with dopamine agonists (DA) delays the incidence of motor complications, but is associated with inferior motor control and a higher frequency of non-motor adverse events (AE) ... Read more...

An evaluation of extracts of five traditional medicinal plants from Iran on the inhibition of mushroom tyrosinase activity and scavenging of free radicals.

29 Sep 2009 This study aimed to evaluate the free radical scavenging and inhibition properties of five medicinal plants, including Quercus infectoria Olive., Terminalia chebula Retz., Lavendula stoechas L., Mentha longifolia L., Rheum palmatum L., toward the ... Read more...

Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia.

21 Sep 2009 Dopamine replacement therapy for the treatment of Parkinson's disease leads to deleterious abnormal involuntary movements (AIMs), known as L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia, which parallels enhanced striatal dopamine D1 ... Read more...

Latest indexed articles for 'Levodopa'

These are the very latest articles for this heading:

• [Dopamine agonist therapy in early Parkinson's disease. A survey of a Cochrane review] 3 Oct 2009
• An evaluation of extracts of five traditional medicinal plants from Iran on the inhibition of mushroom tyrosinase activity and scavenging of free radicals. 29 Sep 2009
• Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia. 21 Sep 2009
• Reduction of the postexcitatory cortical inhibition upon paired-click auditory stimulation in patients with Parkinson's disease. 17 Sep 2009
• Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study. 14 Sep 2009
• Does subthalamotomy have a place in the treatment of Parkinson's disease? 30 Aug 2009
• Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats. 25 Aug 2009
• [Management of Parkinson's disease in 2009] 24 Aug 2009
• Dopamine agonists in 6-pyruvoyl tetrahydropterin synthase deficiency. 23 Aug 2009
• Amphetamine reduces vesicular dopamine content in dexamethasone-differentiated PC12 cells only following L-DOPA exposure. 20 Aug 2009
• Medical treatment of Parkinson disease. 30 Jul 2009
• Visualizing vesicular dopamine dynamics in Parkinson's disease. 30 Jul 2009
• Does imatinib mesylate therapy cause growth hormone deficiency? 29 Jul 2009
• Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. 28 Jul 2009
• Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents. 26 Jul 2009
• Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa. 21 Jul 2009
• Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. 19 Jul 2009
• Thwarting dyskinesia by targeting mTORC1. 19 Jul 2009
• Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. 16 Jul 2009
• Homocysteine levels after acute levodopa intake in patients with Parkinson's disease. 13 Jul 2009

See a longer list of these articles.

Technical information about 'Levodopa'

Definition: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.

Registry Number: 0

Descriptor UI: D007980

Alternative terms: Levodopa; L-Dopa; L Dopa; 3-Hydroxy-L-tyrosine; 3 Hydroxy L tyrosine; L-3,4-Dihydroxyphenylalanine; L 3,4 Dihydroxyphenylalanine; Levopa; Dopar; Roberts Brand of Levodopa; Larodopa; Roche Brand of Levodopa; Dopaflex; Medphano Brand of Levodopa;

Related Mesh Headings: Dopamine;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antiparkinson Agents; Dopamine Agents;

Tree Number: D02.092.311.200.480; D12.125.072.050.685.400.500; D12.125.072.050.875.130.500;

Online Note: search DOPA 1972-74

History Note: 75; was see DOPA 1972-74